nodes	percent_of_prediction	percent_of_DWPC	metapath
Citalopram—CYP2E1—prostate cancer	0.111	0.382	CbGaD
Citalopram—CYP2C19—prostate cancer	0.11	0.378	CbGaD
Citalopram—CYP3A4—prostate cancer	0.0698	0.24	CbGaD
Citalopram—CYP2C19—Bicalutamide—prostate cancer	0.021	0.0519	CbGbCtD
Citalopram—CYP2C19—Nilutamide—prostate cancer	0.021	0.0519	CbGbCtD
Citalopram—CYP2E1—Estrone—prostate cancer	0.02	0.0496	CbGbCtD
Citalopram—CYP2B6—Estrone—prostate cancer	0.0198	0.0489	CbGbCtD
Citalopram—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.0193	0.0477	CbGbCtD
Citalopram—CYP2B6—Ethinyl Estradiol—prostate cancer	0.0176	0.0436	CbGbCtD
Citalopram—CYP2C19—Flutamide—prostate cancer	0.0174	0.043	CbGbCtD
Citalopram—CYP1A2—Flutamide—prostate cancer	0.016	0.0397	CbGbCtD
Citalopram—CYP2D6—Bicalutamide—prostate cancer	0.0159	0.0394	CbGbCtD
Citalopram—ABCB1—Estramustine—prostate cancer	0.0157	0.0389	CbGbCtD
Citalopram—CYP2D6—Abiraterone—prostate cancer	0.0132	0.0327	CbGbCtD
Citalopram—CYP2E1—Mitoxantrone—prostate cancer	0.0119	0.0295	CbGbCtD
Citalopram—CYP1A2—Estrone—prostate cancer	0.0116	0.0287	CbGbCtD
Citalopram—ABCB1—Cabazitaxel—prostate cancer	0.0104	0.0256	CbGbCtD
Citalopram—CYP3A4—Bicalutamide—prostate cancer	0.0101	0.0251	CbGbCtD
Citalopram—ABCB1—Estrone—prostate cancer	0.0101	0.0251	CbGbCtD
Citalopram—CYP3A4—Estramustine—prostate cancer	0.00942	0.0233	CbGbCtD
Citalopram—ABCB1—Ethinyl Estradiol—prostate cancer	0.00903	0.0223	CbGbCtD
Citalopram—CYP3A4—Abiraterone—prostate cancer	0.00839	0.0208	CbGbCtD
Citalopram—CYP3A4—Flutamide—prostate cancer	0.00839	0.0208	CbGbCtD
Citalopram—CYP1A2—Conjugated Estrogens—prostate cancer	0.00758	0.0188	CbGbCtD
Citalopram—CYP2E1—Etoposide—prostate cancer	0.00751	0.0186	CbGbCtD
Citalopram—CYP2C19—Estradiol—prostate cancer	0.00721	0.0178	CbGbCtD
Citalopram—CYP1A2—Estradiol—prostate cancer	0.00665	0.0165	CbGbCtD
Citalopram—ABCB1—Conjugated Estrogens—prostate cancer	0.00663	0.0164	CbGbCtD
Citalopram—CYP3A4—Cabazitaxel—prostate cancer	0.00621	0.0154	CbGbCtD
Citalopram—CYP2C19—Prednisone—prostate cancer	0.0062	0.0153	CbGbCtD
Citalopram—CYP3A4—Estrone—prostate cancer	0.00607	0.015	CbGbCtD
Citalopram—ABCB1—Mitoxantrone—prostate cancer	0.00602	0.0149	CbGbCtD
Citalopram—ABCB1—Estradiol—prostate cancer	0.00582	0.0144	CbGbCtD
Citalopram—CYP3A4—Ethinyl Estradiol—prostate cancer	0.00541	0.0134	CbGbCtD
Citalopram—CYP2B6—Doxorubicin—prostate cancer	0.00505	0.0125	CbGbCtD
Citalopram—ABCB1—Prednisone—prostate cancer	0.005	0.0124	CbGbCtD
Citalopram—CYP1A2—Etoposide—prostate cancer	0.00434	0.0108	CbGbCtD
Citalopram—CYP3A4—Conjugated Estrogens—prostate cancer	0.00397	0.00983	CbGbCtD
Citalopram—ABCB1—Etoposide—prostate cancer	0.0038	0.0094	CbGbCtD
Citalopram—CYP3A4—Mitoxantrone—prostate cancer	0.00361	0.00893	CbGbCtD
Citalopram—CYP3A4—Estradiol—prostate cancer	0.00349	0.00863	CbGbCtD
Citalopram—ABCB1—Docetaxel—prostate cancer	0.00348	0.0086	CbGbCtD
Citalopram—CYP3A4—Prednisone—prostate cancer	0.003	0.00742	CbGbCtD
Citalopram—ABCB1—Doxorubicin—prostate cancer	0.00259	0.00641	CbGbCtD
Citalopram—CYP2D6—Doxorubicin—prostate cancer	0.00244	0.00604	CbGbCtD
Citalopram—CYP3A4—Etoposide—prostate cancer	0.00228	0.00563	CbGbCtD
Citalopram—CYP3A4—Docetaxel—prostate cancer	0.00208	0.00515	CbGbCtD
Citalopram—CYP2C19—urine—prostate cancer	0.00158	0.111	CbGeAlD
Citalopram—CYP3A4—Doxorubicin—prostate cancer	0.00155	0.00384	CbGbCtD
Citalopram—CYP1A2—urine—prostate cancer	0.00129	0.0906	CbGeAlD
Citalopram—CYP2E1—urine—prostate cancer	0.00116	0.0815	CbGeAlD
Citalopram—Escitalopram—CYP2C19—prostate cancer	0.00114	0.611	CrCbGaD
Citalopram—CYP3A4—urine—prostate cancer	0.000934	0.0656	CbGeAlD
Citalopram—CYP2D6—urine—prostate cancer	0.000919	0.0645	CbGeAlD
Citalopram—Escitalopram—CYP3A4—prostate cancer	0.000725	0.389	CrCbGaD
Citalopram—CHRM1—prostate gland—prostate cancer	0.000682	0.0479	CbGeAlD
Citalopram—ADRA1A—prostate gland—prostate cancer	0.00056	0.0393	CbGeAlD
Citalopram—HRH1—prostate gland—prostate cancer	0.000433	0.0304	CbGeAlD
Citalopram—CYP2E1—prostate gland—prostate cancer	0.000417	0.0293	CbGeAlD
Citalopram—ADRA1A—epithelium—prostate cancer	0.000411	0.0289	CbGeAlD
Citalopram—ADRA1A—renal system—prostate cancer	0.000382	0.0268	CbGeAlD
Citalopram—CYP2E1—seminal vesicle—prostate cancer	0.000352	0.0247	CbGeAlD
Citalopram—SLC6A3—testis—prostate cancer	0.000329	0.0231	CbGeAlD
Citalopram—HRH1—epithelium—prostate cancer	0.000319	0.0224	CbGeAlD
Citalopram—CYP1A2—renal system—prostate cancer	0.000316	0.0222	CbGeAlD
Citalopram—CYP2B6—renal system—prostate cancer	0.000303	0.0213	CbGeAlD
Citalopram—HRH1—urethra—prostate cancer	0.00029	0.0204	CbGeAlD
Citalopram—CYP2E1—renal system—prostate cancer	0.000284	0.0199	CbGeAlD
Citalopram—CYP2E1—urethra—prostate cancer	0.000279	0.0196	CbGeAlD
Citalopram—SLC6A2—testis—prostate cancer	0.000265	0.0186	CbGeAlD
Citalopram—ABCB1—prostate gland—prostate cancer	0.000237	0.0167	CbGeAlD
Citalopram—CYP3A4—renal system—prostate cancer	0.000228	0.016	CbGeAlD
Citalopram—CYP2D6—renal system—prostate cancer	0.000225	0.0158	CbGeAlD
Citalopram—ABCB1—seminal vesicle—prostate cancer	0.000201	0.0141	CbGeAlD
Citalopram—CYP2B6—testis—prostate cancer	0.000196	0.0137	CbGeAlD
Citalopram—SLC6A2—lymph node—prostate cancer	0.000192	0.0135	CbGeAlD
Citalopram—HRH1—testis—prostate cancer	0.000191	0.0134	CbGeAlD
Citalopram—CYP2E1—testis—prostate cancer	0.000183	0.0129	CbGeAlD
Citalopram—ABCB1—epithelium—prostate cancer	0.000174	0.0122	CbGeAlD
Citalopram—ABCB1—renal system—prostate cancer	0.000162	0.0114	CbGeAlD
Citalopram—ABCB1—urethra—prostate cancer	0.000159	0.0112	CbGeAlD
Citalopram—CYP2D6—testis—prostate cancer	0.000145	0.0102	CbGeAlD
Citalopram—HRH1—lymph node—prostate cancer	0.000138	0.00972	CbGeAlD
Citalopram—ABCB1—bone marrow—prostate cancer	0.000122	0.00859	CbGeAlD
Citalopram—ABCB1—testis—prostate cancer	0.000105	0.00734	CbGeAlD
Citalopram—ABCB1—lymph node—prostate cancer	7.58e-05	0.00532	CbGeAlD
Citalopram—Haemoglobin—Doxorubicin—prostate cancer	1.43e-05	7.28e-05	CcSEcCtD
Citalopram—Musculoskeletal discomfort—Capecitabine—prostate cancer	1.43e-05	7.27e-05	CcSEcCtD
Citalopram—Flushing—Epirubicin—prostate cancer	1.43e-05	7.26e-05	CcSEcCtD
Citalopram—Cardiac disorder—Epirubicin—prostate cancer	1.43e-05	7.26e-05	CcSEcCtD
Citalopram—Rhinitis—Doxorubicin—prostate cancer	1.43e-05	7.26e-05	CcSEcCtD
Citalopram—Dyspepsia—Docetaxel—prostate cancer	1.43e-05	7.26e-05	CcSEcCtD
Citalopram—Hepatitis—Doxorubicin—prostate cancer	1.42e-05	7.24e-05	CcSEcCtD
Citalopram—Haemorrhage—Doxorubicin—prostate cancer	1.42e-05	7.24e-05	CcSEcCtD
Citalopram—Insomnia—Capecitabine—prostate cancer	1.42e-05	7.22e-05	CcSEcCtD
Citalopram—Hypoaesthesia—Doxorubicin—prostate cancer	1.42e-05	7.2e-05	CcSEcCtD
Citalopram—Pharyngitis—Doxorubicin—prostate cancer	1.41e-05	7.19e-05	CcSEcCtD
Citalopram—Paraesthesia—Capecitabine—prostate cancer	1.41e-05	7.17e-05	CcSEcCtD
Citalopram—Decreased appetite—Docetaxel—prostate cancer	1.41e-05	7.17e-05	CcSEcCtD
Citalopram—Urinary tract disorder—Doxorubicin—prostate cancer	1.41e-05	7.15e-05	CcSEcCtD
Citalopram—Oedema peripheral—Doxorubicin—prostate cancer	1.4e-05	7.13e-05	CcSEcCtD
Citalopram—Gastrointestinal disorder—Docetaxel—prostate cancer	1.4e-05	7.12e-05	CcSEcCtD
Citalopram—Asthenia—Etoposide—prostate cancer	1.4e-05	7.12e-05	CcSEcCtD
Citalopram—Connective tissue disorder—Doxorubicin—prostate cancer	1.4e-05	7.12e-05	CcSEcCtD
Citalopram—Dyspnoea—Capecitabine—prostate cancer	1.4e-05	7.12e-05	CcSEcCtD
Citalopram—Oedema—Prednisone—prostate cancer	1.4e-05	7.11e-05	CcSEcCtD
Citalopram—Anaphylactic shock—Prednisone—prostate cancer	1.4e-05	7.11e-05	CcSEcCtD
Citalopram—Fatigue—Docetaxel—prostate cancer	1.4e-05	7.11e-05	CcSEcCtD
Citalopram—Angiopathy—Epirubicin—prostate cancer	1.4e-05	7.1e-05	CcSEcCtD
Citalopram—Urethral disorder—Doxorubicin—prostate cancer	1.4e-05	7.1e-05	CcSEcCtD
Citalopram—Nausea—Mitoxantrone—prostate cancer	1.39e-05	7.08e-05	CcSEcCtD
Citalopram—Immune system disorder—Epirubicin—prostate cancer	1.39e-05	7.07e-05	CcSEcCtD
Citalopram—Infection—Prednisone—prostate cancer	1.39e-05	7.06e-05	CcSEcCtD
Citalopram—Mediastinal disorder—Epirubicin—prostate cancer	1.39e-05	7.05e-05	CcSEcCtD
Citalopram—Pain—Docetaxel—prostate cancer	1.39e-05	7.05e-05	CcSEcCtD
Citalopram—Constipation—Docetaxel—prostate cancer	1.39e-05	7.05e-05	CcSEcCtD
Citalopram—Dyspepsia—Capecitabine—prostate cancer	1.38e-05	7.03e-05	CcSEcCtD
Citalopram—Chills—Epirubicin—prostate cancer	1.38e-05	7.02e-05	CcSEcCtD
Citalopram—Pruritus—Etoposide—prostate cancer	1.38e-05	7.02e-05	CcSEcCtD
Citalopram—Shock—Prednisone—prostate cancer	1.38e-05	6.99e-05	CcSEcCtD
Citalopram—Arrhythmia—Epirubicin—prostate cancer	1.38e-05	6.99e-05	CcSEcCtD
Citalopram—Visual impairment—Doxorubicin—prostate cancer	1.37e-05	6.98e-05	CcSEcCtD
Citalopram—Nervous system disorder—Prednisone—prostate cancer	1.37e-05	6.97e-05	CcSEcCtD
Citalopram—Tachycardia—Prednisone—prostate cancer	1.36e-05	6.94e-05	CcSEcCtD
Citalopram—Decreased appetite—Capecitabine—prostate cancer	1.36e-05	6.94e-05	CcSEcCtD
Citalopram—Alopecia—Epirubicin—prostate cancer	1.36e-05	6.92e-05	CcSEcCtD
Citalopram—Skin disorder—Prednisone—prostate cancer	1.36e-05	6.9e-05	CcSEcCtD
Citalopram—Gastrointestinal disorder—Capecitabine—prostate cancer	1.36e-05	6.89e-05	CcSEcCtD
Citalopram—Fatigue—Capecitabine—prostate cancer	1.35e-05	6.88e-05	CcSEcCtD
Citalopram—Hyperhidrosis—Prednisone—prostate cancer	1.35e-05	6.87e-05	CcSEcCtD
Citalopram—Mental disorder—Epirubicin—prostate cancer	1.35e-05	6.86e-05	CcSEcCtD
Citalopram—Erythema multiforme—Doxorubicin—prostate cancer	1.35e-05	6.85e-05	CcSEcCtD
Citalopram—Pain—Capecitabine—prostate cancer	1.34e-05	6.82e-05	CcSEcCtD
Citalopram—Constipation—Capecitabine—prostate cancer	1.34e-05	6.82e-05	CcSEcCtD
Citalopram—Malnutrition—Epirubicin—prostate cancer	1.34e-05	6.81e-05	CcSEcCtD
Citalopram—Erythema—Epirubicin—prostate cancer	1.34e-05	6.81e-05	CcSEcCtD
Citalopram—Feeling abnormal—Docetaxel—prostate cancer	1.34e-05	6.79e-05	CcSEcCtD
Citalopram—Diarrhoea—Etoposide—prostate cancer	1.33e-05	6.79e-05	CcSEcCtD
Citalopram—Anorexia—Prednisone—prostate cancer	1.33e-05	6.78e-05	CcSEcCtD
Citalopram—Eye disorder—Doxorubicin—prostate cancer	1.33e-05	6.77e-05	CcSEcCtD
Citalopram—Tinnitus—Doxorubicin—prostate cancer	1.33e-05	6.75e-05	CcSEcCtD
Citalopram—Gastrointestinal pain—Docetaxel—prostate cancer	1.33e-05	6.74e-05	CcSEcCtD
Citalopram—Flushing—Doxorubicin—prostate cancer	1.32e-05	6.72e-05	CcSEcCtD
Citalopram—Cardiac disorder—Doxorubicin—prostate cancer	1.32e-05	6.72e-05	CcSEcCtD
Citalopram—Flatulence—Epirubicin—prostate cancer	1.32e-05	6.71e-05	CcSEcCtD
Citalopram—Tension—Epirubicin—prostate cancer	1.31e-05	6.68e-05	CcSEcCtD
Citalopram—Dysgeusia—Epirubicin—prostate cancer	1.31e-05	6.67e-05	CcSEcCtD
Citalopram—Nervousness—Epirubicin—prostate cancer	1.3e-05	6.62e-05	CcSEcCtD
Citalopram—Back pain—Epirubicin—prostate cancer	1.3e-05	6.59e-05	CcSEcCtD
Citalopram—Feeling abnormal—Capecitabine—prostate cancer	1.29e-05	6.58e-05	CcSEcCtD
Citalopram—Angiopathy—Doxorubicin—prostate cancer	1.29e-05	6.57e-05	CcSEcCtD
Citalopram—Dizziness—Etoposide—prostate cancer	1.29e-05	6.56e-05	CcSEcCtD
Citalopram—Muscle spasms—Epirubicin—prostate cancer	1.29e-05	6.55e-05	CcSEcCtD
Citalopram—Immune system disorder—Doxorubicin—prostate cancer	1.29e-05	6.54e-05	CcSEcCtD
Citalopram—Gastrointestinal pain—Capecitabine—prostate cancer	1.28e-05	6.53e-05	CcSEcCtD
Citalopram—Mediastinal disorder—Doxorubicin—prostate cancer	1.28e-05	6.53e-05	CcSEcCtD
Citalopram—Abdominal pain—Docetaxel—prostate cancer	1.28e-05	6.52e-05	CcSEcCtD
Citalopram—Body temperature increased—Docetaxel—prostate cancer	1.28e-05	6.52e-05	CcSEcCtD
Citalopram—Chills—Doxorubicin—prostate cancer	1.28e-05	6.5e-05	CcSEcCtD
Citalopram—Musculoskeletal discomfort—Prednisone—prostate cancer	1.27e-05	6.48e-05	CcSEcCtD
Citalopram—Arrhythmia—Doxorubicin—prostate cancer	1.27e-05	6.47e-05	CcSEcCtD
Citalopram—Insomnia—Prednisone—prostate cancer	1.26e-05	6.43e-05	CcSEcCtD
Citalopram—Vision blurred—Epirubicin—prostate cancer	1.26e-05	6.42e-05	CcSEcCtD
Citalopram—Alopecia—Doxorubicin—prostate cancer	1.26e-05	6.4e-05	CcSEcCtD
Citalopram—Paraesthesia—Prednisone—prostate cancer	1.26e-05	6.38e-05	CcSEcCtD
Citalopram—Mental disorder—Doxorubicin—prostate cancer	1.25e-05	6.34e-05	CcSEcCtD
Citalopram—Urticaria—Capecitabine—prostate cancer	1.25e-05	6.34e-05	CcSEcCtD
Citalopram—Ill-defined disorder—Epirubicin—prostate cancer	1.24e-05	6.32e-05	CcSEcCtD
Citalopram—Abdominal pain—Capecitabine—prostate cancer	1.24e-05	6.31e-05	CcSEcCtD
Citalopram—Body temperature increased—Capecitabine—prostate cancer	1.24e-05	6.31e-05	CcSEcCtD
Citalopram—Vomiting—Etoposide—prostate cancer	1.24e-05	6.31e-05	CcSEcCtD
Citalopram—Malnutrition—Doxorubicin—prostate cancer	1.24e-05	6.3e-05	CcSEcCtD
Citalopram—Erythema—Doxorubicin—prostate cancer	1.24e-05	6.3e-05	CcSEcCtD
Citalopram—Anaemia—Epirubicin—prostate cancer	1.24e-05	6.3e-05	CcSEcCtD
Citalopram—Agitation—Epirubicin—prostate cancer	1.23e-05	6.26e-05	CcSEcCtD
Citalopram—Dyspepsia—Prednisone—prostate cancer	1.23e-05	6.26e-05	CcSEcCtD
Citalopram—Rash—Etoposide—prostate cancer	1.23e-05	6.25e-05	CcSEcCtD
Citalopram—Dermatitis—Etoposide—prostate cancer	1.23e-05	6.25e-05	CcSEcCtD
Citalopram—Headache—Etoposide—prostate cancer	1.22e-05	6.21e-05	CcSEcCtD
Citalopram—Flatulence—Doxorubicin—prostate cancer	1.22e-05	6.21e-05	CcSEcCtD
Citalopram—Tension—Doxorubicin—prostate cancer	1.22e-05	6.19e-05	CcSEcCtD
Citalopram—Decreased appetite—Prednisone—prostate cancer	1.22e-05	6.18e-05	CcSEcCtD
Citalopram—Dysgeusia—Doxorubicin—prostate cancer	1.21e-05	6.17e-05	CcSEcCtD
Citalopram—Malaise—Epirubicin—prostate cancer	1.21e-05	6.14e-05	CcSEcCtD
Citalopram—Fatigue—Prednisone—prostate cancer	1.21e-05	6.13e-05	CcSEcCtD
Citalopram—Nervousness—Doxorubicin—prostate cancer	1.2e-05	6.12e-05	CcSEcCtD
Citalopram—Vertigo—Epirubicin—prostate cancer	1.2e-05	6.12e-05	CcSEcCtD
Citalopram—Syncope—Epirubicin—prostate cancer	1.2e-05	6.11e-05	CcSEcCtD
Citalopram—Leukopenia—Epirubicin—prostate cancer	1.2e-05	6.1e-05	CcSEcCtD
Citalopram—Back pain—Doxorubicin—prostate cancer	1.2e-05	6.1e-05	CcSEcCtD
Citalopram—Constipation—Prednisone—prostate cancer	1.2e-05	6.08e-05	CcSEcCtD
Citalopram—Hypersensitivity—Docetaxel—prostate cancer	1.19e-05	6.07e-05	CcSEcCtD
Citalopram—Muscle spasms—Doxorubicin—prostate cancer	1.19e-05	6.06e-05	CcSEcCtD
Citalopram—Palpitations—Epirubicin—prostate cancer	1.18e-05	6.02e-05	CcSEcCtD
Citalopram—Loss of consciousness—Epirubicin—prostate cancer	1.18e-05	5.99e-05	CcSEcCtD
Citalopram—Cough—Epirubicin—prostate cancer	1.17e-05	5.94e-05	CcSEcCtD
Citalopram—Vision blurred—Doxorubicin—prostate cancer	1.17e-05	5.94e-05	CcSEcCtD
Citalopram—Asthenia—Docetaxel—prostate cancer	1.16e-05	5.91e-05	CcSEcCtD
Citalopram—Convulsion—Epirubicin—prostate cancer	1.16e-05	5.9e-05	CcSEcCtD
Citalopram—Nausea—Etoposide—prostate cancer	1.16e-05	5.89e-05	CcSEcCtD
Citalopram—Hypertension—Epirubicin—prostate cancer	1.16e-05	5.88e-05	CcSEcCtD
Citalopram—Hypersensitivity—Capecitabine—prostate cancer	1.16e-05	5.88e-05	CcSEcCtD
Citalopram—Feeling abnormal—Prednisone—prostate cancer	1.15e-05	5.86e-05	CcSEcCtD
Citalopram—Ill-defined disorder—Doxorubicin—prostate cancer	1.15e-05	5.85e-05	CcSEcCtD
Citalopram—Pruritus—Docetaxel—prostate cancer	1.15e-05	5.83e-05	CcSEcCtD
Citalopram—Anaemia—Doxorubicin—prostate cancer	1.15e-05	5.83e-05	CcSEcCtD
Citalopram—Gastrointestinal pain—Prednisone—prostate cancer	1.14e-05	5.81e-05	CcSEcCtD
Citalopram—Arthralgia—Epirubicin—prostate cancer	1.14e-05	5.8e-05	CcSEcCtD
Citalopram—Chest pain—Epirubicin—prostate cancer	1.14e-05	5.8e-05	CcSEcCtD
Citalopram—Myalgia—Epirubicin—prostate cancer	1.14e-05	5.8e-05	CcSEcCtD
Citalopram—Agitation—Doxorubicin—prostate cancer	1.14e-05	5.79e-05	CcSEcCtD
Citalopram—Anxiety—Epirubicin—prostate cancer	1.14e-05	5.78e-05	CcSEcCtD
Citalopram—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	1.13e-05	5.76e-05	CcSEcCtD
Citalopram—Discomfort—Epirubicin—prostate cancer	1.13e-05	5.73e-05	CcSEcCtD
Citalopram—Asthenia—Capecitabine—prostate cancer	1.13e-05	5.73e-05	CcSEcCtD
Citalopram—Malaise—Doxorubicin—prostate cancer	1.12e-05	5.68e-05	CcSEcCtD
Citalopram—Dry mouth—Epirubicin—prostate cancer	1.12e-05	5.67e-05	CcSEcCtD
Citalopram—Vertigo—Doxorubicin—prostate cancer	1.11e-05	5.66e-05	CcSEcCtD
Citalopram—Syncope—Doxorubicin—prostate cancer	1.11e-05	5.65e-05	CcSEcCtD
Citalopram—Urticaria—Prednisone—prostate cancer	1.11e-05	5.65e-05	CcSEcCtD
Citalopram—Pruritus—Capecitabine—prostate cancer	1.11e-05	5.65e-05	CcSEcCtD
Citalopram—Leukopenia—Doxorubicin—prostate cancer	1.11e-05	5.64e-05	CcSEcCtD
Citalopram—Diarrhoea—Docetaxel—prostate cancer	1.11e-05	5.64e-05	CcSEcCtD
Citalopram—Abdominal pain—Prednisone—prostate cancer	1.11e-05	5.62e-05	CcSEcCtD
Citalopram—Body temperature increased—Prednisone—prostate cancer	1.11e-05	5.62e-05	CcSEcCtD
Citalopram—Confusional state—Epirubicin—prostate cancer	1.1e-05	5.61e-05	CcSEcCtD
Citalopram—Palpitations—Doxorubicin—prostate cancer	1.1e-05	5.57e-05	CcSEcCtD
Citalopram—Anaphylactic shock—Epirubicin—prostate cancer	1.09e-05	5.56e-05	CcSEcCtD
Citalopram—Oedema—Epirubicin—prostate cancer	1.09e-05	5.56e-05	CcSEcCtD
Citalopram—Loss of consciousness—Doxorubicin—prostate cancer	1.09e-05	5.54e-05	CcSEcCtD
Citalopram—Infection—Epirubicin—prostate cancer	1.09e-05	5.52e-05	CcSEcCtD
Citalopram—Cough—Doxorubicin—prostate cancer	1.08e-05	5.5e-05	CcSEcCtD
Citalopram—Shock—Epirubicin—prostate cancer	1.08e-05	5.47e-05	CcSEcCtD
Citalopram—Convulsion—Doxorubicin—prostate cancer	1.07e-05	5.46e-05	CcSEcCtD
Citalopram—Diarrhoea—Capecitabine—prostate cancer	1.07e-05	5.46e-05	CcSEcCtD
Citalopram—Nervous system disorder—Epirubicin—prostate cancer	1.07e-05	5.45e-05	CcSEcCtD
Citalopram—Dizziness—Docetaxel—prostate cancer	1.07e-05	5.45e-05	CcSEcCtD
Citalopram—Thrombocytopenia—Epirubicin—prostate cancer	1.07e-05	5.44e-05	CcSEcCtD
Citalopram—Hypertension—Doxorubicin—prostate cancer	1.07e-05	5.44e-05	CcSEcCtD
Citalopram—Tachycardia—Epirubicin—prostate cancer	1.07e-05	5.43e-05	CcSEcCtD
Citalopram—Skin disorder—Epirubicin—prostate cancer	1.06e-05	5.4e-05	CcSEcCtD
Citalopram—Hyperhidrosis—Epirubicin—prostate cancer	1.06e-05	5.37e-05	CcSEcCtD
Citalopram—Arthralgia—Doxorubicin—prostate cancer	1.06e-05	5.37e-05	CcSEcCtD
Citalopram—Chest pain—Doxorubicin—prostate cancer	1.06e-05	5.37e-05	CcSEcCtD
Citalopram—Myalgia—Doxorubicin—prostate cancer	1.06e-05	5.37e-05	CcSEcCtD
Citalopram—Anxiety—Doxorubicin—prostate cancer	1.05e-05	5.35e-05	CcSEcCtD
Citalopram—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	1.05e-05	5.33e-05	CcSEcCtD
Citalopram—Discomfort—Doxorubicin—prostate cancer	1.04e-05	5.3e-05	CcSEcCtD
Citalopram—Anorexia—Epirubicin—prostate cancer	1.04e-05	5.3e-05	CcSEcCtD
Citalopram—Dizziness—Capecitabine—prostate cancer	1.04e-05	5.28e-05	CcSEcCtD
Citalopram—Dry mouth—Doxorubicin—prostate cancer	1.03e-05	5.25e-05	CcSEcCtD
Citalopram—Vomiting—Docetaxel—prostate cancer	1.03e-05	5.24e-05	CcSEcCtD
Citalopram—Hypersensitivity—Prednisone—prostate cancer	1.03e-05	5.24e-05	CcSEcCtD
Citalopram—Rash—Docetaxel—prostate cancer	1.02e-05	5.2e-05	CcSEcCtD
Citalopram—Hypotension—Epirubicin—prostate cancer	1.02e-05	5.2e-05	CcSEcCtD
Citalopram—Dermatitis—Docetaxel—prostate cancer	1.02e-05	5.19e-05	CcSEcCtD
Citalopram—Confusional state—Doxorubicin—prostate cancer	1.02e-05	5.19e-05	CcSEcCtD
Citalopram—Headache—Docetaxel—prostate cancer	1.02e-05	5.16e-05	CcSEcCtD
Citalopram—Oedema—Doxorubicin—prostate cancer	1.01e-05	5.14e-05	CcSEcCtD
Citalopram—Anaphylactic shock—Doxorubicin—prostate cancer	1.01e-05	5.14e-05	CcSEcCtD
Citalopram—Infection—Doxorubicin—prostate cancer	1.01e-05	5.11e-05	CcSEcCtD
Citalopram—Asthenia—Prednisone—prostate cancer	1e-05	5.1e-05	CcSEcCtD
Citalopram—Vomiting—Capecitabine—prostate cancer	9.98e-06	5.07e-05	CcSEcCtD
Citalopram—Musculoskeletal discomfort—Epirubicin—prostate cancer	9.96e-06	5.07e-05	CcSEcCtD
Citalopram—Shock—Doxorubicin—prostate cancer	9.96e-06	5.06e-05	CcSEcCtD
Citalopram—Nervous system disorder—Doxorubicin—prostate cancer	9.92e-06	5.04e-05	CcSEcCtD
Citalopram—Thrombocytopenia—Doxorubicin—prostate cancer	9.91e-06	5.04e-05	CcSEcCtD
Citalopram—Rash—Capecitabine—prostate cancer	9.9e-06	5.03e-05	CcSEcCtD
Citalopram—Pruritus—Prednisone—prostate cancer	9.89e-06	5.03e-05	CcSEcCtD
Citalopram—Insomnia—Epirubicin—prostate cancer	9.89e-06	5.03e-05	CcSEcCtD
Citalopram—Dermatitis—Capecitabine—prostate cancer	9.89e-06	5.03e-05	CcSEcCtD
Citalopram—Tachycardia—Doxorubicin—prostate cancer	9.88e-06	5.02e-05	CcSEcCtD
Citalopram—Headache—Capecitabine—prostate cancer	9.83e-06	5e-05	CcSEcCtD
Citalopram—Skin disorder—Doxorubicin—prostate cancer	9.83e-06	5e-05	CcSEcCtD
Citalopram—Paraesthesia—Epirubicin—prostate cancer	9.82e-06	4.99e-05	CcSEcCtD
Citalopram—Hyperhidrosis—Doxorubicin—prostate cancer	9.78e-06	4.97e-05	CcSEcCtD
Citalopram—Dyspnoea—Epirubicin—prostate cancer	9.75e-06	4.96e-05	CcSEcCtD
Citalopram—Somnolence—Epirubicin—prostate cancer	9.72e-06	4.94e-05	CcSEcCtD
Citalopram—Anorexia—Doxorubicin—prostate cancer	9.65e-06	4.9e-05	CcSEcCtD
Citalopram—Nausea—Docetaxel—prostate cancer	9.63e-06	4.9e-05	CcSEcCtD
Citalopram—Dyspepsia—Epirubicin—prostate cancer	9.63e-06	4.89e-05	CcSEcCtD
Citalopram—Diarrhoea—Prednisone—prostate cancer	9.57e-06	4.86e-05	CcSEcCtD
Citalopram—Decreased appetite—Epirubicin—prostate cancer	9.51e-06	4.83e-05	CcSEcCtD
Citalopram—Hypotension—Doxorubicin—prostate cancer	9.46e-06	4.81e-05	CcSEcCtD
Citalopram—Gastrointestinal disorder—Epirubicin—prostate cancer	9.44e-06	4.8e-05	CcSEcCtD
Citalopram—Fatigue—Epirubicin—prostate cancer	9.43e-06	4.79e-05	CcSEcCtD
Citalopram—Constipation—Epirubicin—prostate cancer	9.35e-06	4.75e-05	CcSEcCtD
Citalopram—Pain—Epirubicin—prostate cancer	9.35e-06	4.75e-05	CcSEcCtD
Citalopram—Nausea—Capecitabine—prostate cancer	9.32e-06	4.74e-05	CcSEcCtD
Citalopram—Dizziness—Prednisone—prostate cancer	9.25e-06	4.7e-05	CcSEcCtD
Citalopram—Musculoskeletal discomfort—Doxorubicin—prostate cancer	9.22e-06	4.69e-05	CcSEcCtD
Citalopram—Insomnia—Doxorubicin—prostate cancer	9.15e-06	4.65e-05	CcSEcCtD
Citalopram—Paraesthesia—Doxorubicin—prostate cancer	9.09e-06	4.62e-05	CcSEcCtD
Citalopram—Dyspnoea—Doxorubicin—prostate cancer	9.02e-06	4.59e-05	CcSEcCtD
Citalopram—Feeling abnormal—Epirubicin—prostate cancer	9.01e-06	4.58e-05	CcSEcCtD
Citalopram—Somnolence—Doxorubicin—prostate cancer	9e-06	4.57e-05	CcSEcCtD
Citalopram—Gastrointestinal pain—Epirubicin—prostate cancer	8.94e-06	4.55e-05	CcSEcCtD
Citalopram—Dyspepsia—Doxorubicin—prostate cancer	8.91e-06	4.53e-05	CcSEcCtD
Citalopram—Vomiting—Prednisone—prostate cancer	8.89e-06	4.52e-05	CcSEcCtD
Citalopram—Rash—Prednisone—prostate cancer	8.82e-06	4.48e-05	CcSEcCtD
Citalopram—Dermatitis—Prednisone—prostate cancer	8.81e-06	4.48e-05	CcSEcCtD
Citalopram—Decreased appetite—Doxorubicin—prostate cancer	8.8e-06	4.47e-05	CcSEcCtD
Citalopram—Headache—Prednisone—prostate cancer	8.76e-06	4.45e-05	CcSEcCtD
Citalopram—Gastrointestinal disorder—Doxorubicin—prostate cancer	8.74e-06	4.44e-05	CcSEcCtD
Citalopram—Fatigue—Doxorubicin—prostate cancer	8.72e-06	4.44e-05	CcSEcCtD
Citalopram—Urticaria—Epirubicin—prostate cancer	8.69e-06	4.42e-05	CcSEcCtD
Citalopram—Pain—Doxorubicin—prostate cancer	8.65e-06	4.4e-05	CcSEcCtD
Citalopram—Constipation—Doxorubicin—prostate cancer	8.65e-06	4.4e-05	CcSEcCtD
Citalopram—Body temperature increased—Epirubicin—prostate cancer	8.64e-06	4.4e-05	CcSEcCtD
Citalopram—Abdominal pain—Epirubicin—prostate cancer	8.64e-06	4.4e-05	CcSEcCtD
Citalopram—Feeling abnormal—Doxorubicin—prostate cancer	8.34e-06	4.24e-05	CcSEcCtD
Citalopram—Nausea—Prednisone—prostate cancer	8.31e-06	4.22e-05	CcSEcCtD
Citalopram—Gastrointestinal pain—Doxorubicin—prostate cancer	8.27e-06	4.21e-05	CcSEcCtD
Citalopram—Hypersensitivity—Epirubicin—prostate cancer	8.06e-06	4.1e-05	CcSEcCtD
Citalopram—Urticaria—Doxorubicin—prostate cancer	8.04e-06	4.09e-05	CcSEcCtD
Citalopram—Abdominal pain—Doxorubicin—prostate cancer	8e-06	4.07e-05	CcSEcCtD
Citalopram—Body temperature increased—Doxorubicin—prostate cancer	8e-06	4.07e-05	CcSEcCtD
Citalopram—Asthenia—Epirubicin—prostate cancer	7.85e-06	3.99e-05	CcSEcCtD
Citalopram—Pruritus—Epirubicin—prostate cancer	7.74e-06	3.93e-05	CcSEcCtD
Citalopram—Diarrhoea—Epirubicin—prostate cancer	7.48e-06	3.8e-05	CcSEcCtD
Citalopram—Hypersensitivity—Doxorubicin—prostate cancer	7.45e-06	3.79e-05	CcSEcCtD
Citalopram—Asthenia—Doxorubicin—prostate cancer	7.26e-06	3.69e-05	CcSEcCtD
Citalopram—Dizziness—Epirubicin—prostate cancer	7.23e-06	3.68e-05	CcSEcCtD
Citalopram—Pruritus—Doxorubicin—prostate cancer	7.16e-06	3.64e-05	CcSEcCtD
Citalopram—Vomiting—Epirubicin—prostate cancer	6.95e-06	3.54e-05	CcSEcCtD
Citalopram—Diarrhoea—Doxorubicin—prostate cancer	6.92e-06	3.52e-05	CcSEcCtD
Citalopram—Rash—Epirubicin—prostate cancer	6.9e-06	3.51e-05	CcSEcCtD
Citalopram—Dermatitis—Epirubicin—prostate cancer	6.89e-06	3.5e-05	CcSEcCtD
Citalopram—Headache—Epirubicin—prostate cancer	6.85e-06	3.48e-05	CcSEcCtD
Citalopram—Dizziness—Doxorubicin—prostate cancer	6.69e-06	3.4e-05	CcSEcCtD
Citalopram—Nausea—Epirubicin—prostate cancer	6.5e-06	3.3e-05	CcSEcCtD
Citalopram—Vomiting—Doxorubicin—prostate cancer	6.43e-06	3.27e-05	CcSEcCtD
Citalopram—Rash—Doxorubicin—prostate cancer	6.38e-06	3.24e-05	CcSEcCtD
Citalopram—Dermatitis—Doxorubicin—prostate cancer	6.37e-06	3.24e-05	CcSEcCtD
Citalopram—Headache—Doxorubicin—prostate cancer	6.34e-06	3.22e-05	CcSEcCtD
Citalopram—Nausea—Doxorubicin—prostate cancer	6.01e-06	3.06e-05	CcSEcCtD
Citalopram—CYP2B6—Metabolism—PIK3CD—prostate cancer	1.78e-06	1.92e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—IGF1—prostate cancer	1.78e-06	1.92e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—MTHFR—prostate cancer	1.78e-06	1.91e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—ERBB2—prostate cancer	1.77e-06	1.91e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	1.77e-06	1.91e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—EGFR—prostate cancer	1.77e-06	1.91e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—COMT—prostate cancer	1.76e-06	1.89e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—NCOA2—prostate cancer	1.75e-06	1.89e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—MAP2K1—prostate cancer	1.75e-06	1.89e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—PIK3CB—prostate cancer	1.75e-06	1.89e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—GSTP1—prostate cancer	1.75e-06	1.88e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—MAP2K1—prostate cancer	1.75e-06	1.88e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—PPARA—prostate cancer	1.74e-06	1.88e-05	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—PIK3CD—prostate cancer	1.74e-06	1.88e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—PIK3CD—prostate cancer	1.74e-06	1.87e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—PIK3CD—prostate cancer	1.74e-06	1.87e-05	CbGpPWpGaD
Citalopram—HRH1—GPCR downstream signaling—PIK3CA—prostate cancer	1.72e-06	1.86e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—SERPINE1—prostate cancer	1.72e-06	1.85e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—MAP2K1—prostate cancer	1.72e-06	1.85e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—ITPR1—prostate cancer	1.72e-06	1.85e-05	CbGpPWpGaD
Citalopram—CHRM1—GPCR downstream signaling—PIK3CA—prostate cancer	1.72e-06	1.85e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—SERPINE1—prostate cancer	1.72e-06	1.85e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—PIK3CD—prostate cancer	1.71e-06	1.84e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—KRAS—prostate cancer	1.7e-06	1.83e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—KRAS—prostate cancer	1.7e-06	1.83e-05	CbGpPWpGaD
Citalopram—ADRA1A—GPCR downstream signaling—PIK3CA—prostate cancer	1.69e-06	1.82e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism of lipids and lipoproteins—EP300—prostate cancer	1.69e-06	1.82e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—SERPINE1—prostate cancer	1.69e-06	1.82e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—CXCL8—prostate cancer	1.68e-06	1.81e-05	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—NOS3—prostate cancer	1.68e-06	1.81e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—CAV1—prostate cancer	1.68e-06	1.81e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—MTHFR—prostate cancer	1.67e-06	1.8e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—SLC5A5—prostate cancer	1.67e-06	1.8e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—KRAS—prostate cancer	1.67e-06	1.8e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—FGF2—prostate cancer	1.67e-06	1.79e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—FGF2—prostate cancer	1.66e-06	1.79e-05	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—NOS3—prostate cancer	1.65e-06	1.77e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—NOS3—prostate cancer	1.64e-06	1.77e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—CDKN1B—prostate cancer	1.64e-06	1.77e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—PPARA—prostate cancer	1.64e-06	1.77e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—CAV1—prostate cancer	1.64e-06	1.76e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—NOS3—prostate cancer	1.64e-06	1.76e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—FGF2—prostate cancer	1.64e-06	1.76e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—CYP2E1—prostate cancer	1.63e-06	1.76e-05	CbGpPWpGaD
Citalopram—HTR2C—GPCR downstream signaling—AKT1—prostate cancer	1.63e-06	1.75e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—TYMS—prostate cancer	1.62e-06	1.75e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—NQO1—prostate cancer	1.62e-06	1.74e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—NOS3—prostate cancer	1.61e-06	1.74e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—CASP3—prostate cancer	1.61e-06	1.73e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—IL2—prostate cancer	1.61e-06	1.73e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—GSTM1—prostate cancer	1.61e-06	1.73e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	1.6e-06	1.73e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—IL6—prostate cancer	1.6e-06	1.72e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—JAK2—prostate cancer	1.6e-06	1.72e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—TH—prostate cancer	1.59e-06	1.71e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—JAK2—prostate cancer	1.59e-06	1.71e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—LPL—prostate cancer	1.58e-06	1.7e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—CCND1—prostate cancer	1.57e-06	1.69e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—JAK2—prostate cancer	1.57e-06	1.69e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—PIK3CA—prostate cancer	1.57e-06	1.69e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—PIK3CA—prostate cancer	1.56e-06	1.68e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—MDM2—prostate cancer	1.56e-06	1.68e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—MDM2—prostate cancer	1.55e-06	1.67e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—CTNNB1—prostate cancer	1.55e-06	1.67e-05	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—PIK3CB—prostate cancer	1.55e-06	1.67e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—CYP1B1—prostate cancer	1.55e-06	1.67e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—CAV1—prostate cancer	1.54e-06	1.66e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—ERBB2—prostate cancer	1.54e-06	1.66e-05	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—PTGS2—prostate cancer	1.54e-06	1.65e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—PIK3CA—prostate cancer	1.54e-06	1.65e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—ERBB2—prostate cancer	1.53e-06	1.65e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—MDM2—prostate cancer	1.53e-06	1.65e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—PIK3CG—prostate cancer	1.53e-06	1.65e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—MMP9—prostate cancer	1.52e-06	1.64e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—CYP1A1—prostate cancer	1.52e-06	1.64e-05	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—PIK3CB—prostate cancer	1.52e-06	1.64e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—PIK3CB—prostate cancer	1.52e-06	1.63e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—CDKN1A—prostate cancer	1.52e-06	1.63e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—PTEN—prostate cancer	1.51e-06	1.63e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—PIK3CB—prostate cancer	1.51e-06	1.63e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—ERCC2—prostate cancer	1.51e-06	1.62e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—ERBB2—prostate cancer	1.51e-06	1.62e-05	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—PTGS2—prostate cancer	1.51e-06	1.62e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—GGT1—prostate cancer	1.5e-06	1.62e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—PIK3CG—prostate cancer	1.49e-06	1.61e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—PIK3CB—prostate cancer	1.49e-06	1.6e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—NCOA1—prostate cancer	1.48e-06	1.59e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—AKT1—prostate cancer	1.48e-06	1.59e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—CXCL8—prostate cancer	1.46e-06	1.57e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—CYP19A1—prostate cancer	1.46e-06	1.57e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—CXCL8—prostate cancer	1.45e-06	1.56e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—INS—prostate cancer	1.45e-06	1.56e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—EP300—prostate cancer	1.44e-06	1.55e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—CXCL8—prostate cancer	1.43e-06	1.54e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—CDKN1B—prostate cancer	1.42e-06	1.53e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—CDKN1B—prostate cancer	1.42e-06	1.53e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—MTHFR—prostate cancer	1.42e-06	1.53e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—CREBBP—prostate cancer	1.42e-06	1.53e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—INS—prostate cancer	1.41e-06	1.52e-05	CbGpPWpGaD
Citalopram—HRH1—GPCR downstream signaling—AKT1—prostate cancer	1.41e-06	1.52e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—PIK3CG—prostate cancer	1.41e-06	1.51e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—RXRA—prostate cancer	1.41e-06	1.51e-05	CbGpPWpGaD
Citalopram—CHRM1—GPCR downstream signaling—AKT1—prostate cancer	1.4e-06	1.51e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—SRC—prostate cancer	1.4e-06	1.51e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—CDKN1B—prostate cancer	1.4e-06	1.5e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—CASP3—prostate cancer	1.4e-06	1.5e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—IL2—prostate cancer	1.39e-06	1.5e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—PPARA—prostate cancer	1.39e-06	1.5e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—CASP3—prostate cancer	1.39e-06	1.5e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—IL2—prostate cancer	1.39e-06	1.5e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—IL6—prostate cancer	1.39e-06	1.49e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—CREBBP—prostate cancer	1.38e-06	1.49e-05	CbGpPWpGaD
Citalopram—ADRA1A—GPCR downstream signaling—AKT1—prostate cancer	1.38e-06	1.49e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—IL6—prostate cancer	1.38e-06	1.49e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—CASP3—prostate cancer	1.37e-06	1.47e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—IL2—prostate cancer	1.37e-06	1.47e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—VEGFA—prostate cancer	1.37e-06	1.47e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—IL6—prostate cancer	1.36e-06	1.46e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—CCND1—prostate cancer	1.36e-06	1.46e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—COMT—prostate cancer	1.35e-06	1.46e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—CCND1—prostate cancer	1.35e-06	1.46e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—STAT3—prostate cancer	1.35e-06	1.46e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—GSTP1—prostate cancer	1.35e-06	1.45e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—CTNNB1—prostate cancer	1.35e-06	1.45e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—PIK3CD—prostate cancer	1.35e-06	1.45e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—CTNNB1—prostate cancer	1.34e-06	1.44e-05	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—PTEN—prostate cancer	1.34e-06	1.44e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—CCND1—prostate cancer	1.33e-06	1.44e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—INS—prostate cancer	1.33e-06	1.43e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—ITPR1—prostate cancer	1.33e-06	1.43e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—CTNNB1—prostate cancer	1.32e-06	1.42e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—MMP9—prostate cancer	1.32e-06	1.42e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—MMP9—prostate cancer	1.31e-06	1.42e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—CDKN1A—prostate cancer	1.31e-06	1.41e-05	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—PTEN—prostate cancer	1.31e-06	1.41e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—PIK3CD—prostate cancer	1.31e-06	1.41e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—PTEN—prostate cancer	1.31e-06	1.41e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—CDKN1A—prostate cancer	1.31e-06	1.41e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—CAV1—prostate cancer	1.31e-06	1.41e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—PTEN—prostate cancer	1.31e-06	1.41e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—CREBBP—prostate cancer	1.3e-06	1.4e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—MMP9—prostate cancer	1.29e-06	1.39e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—CDKN1A—prostate cancer	1.29e-06	1.39e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—PTEN—prostate cancer	1.29e-06	1.39e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—AKT1—prostate cancer	1.28e-06	1.38e-05	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—EP300—prostate cancer	1.28e-06	1.38e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—AKT1—prostate cancer	1.28e-06	1.37e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—NOS3—prostate cancer	1.27e-06	1.37e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—MYC—prostate cancer	1.26e-06	1.35e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—AKT1—prostate cancer	1.26e-06	1.35e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—TGFB1—prostate cancer	1.25e-06	1.35e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—TYMS—prostate cancer	1.25e-06	1.35e-05	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—EP300—prostate cancer	1.25e-06	1.35e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—EP300—prostate cancer	1.25e-06	1.35e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	1.25e-06	1.35e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—EP300—prostate cancer	1.25e-06	1.34e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—NOS3—prostate cancer	1.24e-06	1.33e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—GSTM1—prostate cancer	1.24e-06	1.33e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—PIK3CD—prostate cancer	1.24e-06	1.33e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—EGFR—prostate cancer	1.23e-06	1.32e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—EP300—prostate cancer	1.23e-06	1.32e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—LPL—prostate cancer	1.22e-06	1.31e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—SRC—prostate cancer	1.22e-06	1.31e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—SRC—prostate cancer	1.21e-06	1.3e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—SRC—prostate cancer	1.19e-06	1.28e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—PIK3CG—prostate cancer	1.19e-06	1.28e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—VEGFA—prostate cancer	1.18e-06	1.27e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—VEGFA—prostate cancer	1.18e-06	1.27e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—CYP1A1—prostate cancer	1.17e-06	1.26e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—STAT3—prostate cancer	1.17e-06	1.26e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—PIK3CB—prostate cancer	1.17e-06	1.26e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—STAT3—prostate cancer	1.17e-06	1.26e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—NOS3—prostate cancer	1.17e-06	1.26e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—ERCC2—prostate cancer	1.16e-06	1.25e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—VEGFA—prostate cancer	1.16e-06	1.25e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—KRAS—prostate cancer	1.16e-06	1.25e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—PTGS2—prostate cancer	1.16e-06	1.25e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—STAT3—prostate cancer	1.15e-06	1.24e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—PIK3CB—prostate cancer	1.14e-06	1.23e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—PTGS2—prostate cancer	1.13e-06	1.22e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—INS—prostate cancer	1.13e-06	1.21e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—CREBBP—prostate cancer	1.11e-06	1.19e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—MTHFR—prostate cancer	1.1e-06	1.18e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—MYC—prostate cancer	1.09e-06	1.17e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—TGFB1—prostate cancer	1.09e-06	1.17e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—MYC—prostate cancer	1.09e-06	1.17e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—TGFB1—prostate cancer	1.08e-06	1.17e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—PIK3CB—prostate cancer	1.08e-06	1.16e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—PPARA—prostate cancer	1.07e-06	1.16e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—MYC—prostate cancer	1.07e-06	1.15e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—PTGS2—prostate cancer	1.07e-06	1.15e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—PIK3CA—prostate cancer	1.07e-06	1.15e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—TGFB1—prostate cancer	1.07e-06	1.15e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—EGFR—prostate cancer	1.07e-06	1.15e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—EGFR—prostate cancer	1.06e-06	1.14e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—PIK3CD—prostate cancer	1.05e-06	1.13e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—EGFR—prostate cancer	1.05e-06	1.13e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—TP53—prostate cancer	1.03e-06	1.11e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—PTEN—prostate cancer	1.01e-06	1.09e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—CAV1—prostate cancer	1.01e-06	1.09e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—KRAS—prostate cancer	1.01e-06	1.08e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—KRAS—prostate cancer	1e-06	1.08e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—NOS3—prostate cancer	9.9e-07	1.07e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—PTEN—prostate cancer	9.89e-07	1.06e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—KRAS—prostate cancer	9.88e-07	1.06e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—EP300—prostate cancer	9.66e-07	1.04e-05	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—PIK3CA—prostate cancer	9.46e-07	1.02e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—IL6—prostate cancer	9.45e-07	1.02e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—EP300—prostate cancer	9.43e-07	1.01e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—PTEN—prostate cancer	9.32e-07	1e-05	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—PIK3CA—prostate cancer	9.26e-07	9.97e-06	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—PIK3CA—prostate cancer	9.25e-07	9.96e-06	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—PIK3CA—prostate cancer	9.22e-07	9.93e-06	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—PIK3CG—prostate cancer	9.2e-07	9.9e-06	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—PIK3CB—prostate cancer	9.13e-07	9.83e-06	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—PIK3CA—prostate cancer	9.08e-07	9.77e-06	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—PTGS2—prostate cancer	9.05e-07	9.74e-06	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—TP53—prostate cancer	8.95e-07	9.63e-06	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—TP53—prostate cancer	8.92e-07	9.6e-06	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—EP300—prostate cancer	8.89e-07	9.56e-06	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—TP53—prostate cancer	8.78e-07	9.45e-06	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—AKT1—prostate cancer	8.72e-07	9.39e-06	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—INS—prostate cancer	8.71e-07	9.37e-06	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—CREBBP—prostate cancer	8.53e-07	9.18e-06	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—IL6—prostate cancer	8.19e-07	8.82e-06	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—IL6—prostate cancer	8.17e-07	8.79e-06	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—PIK3CD—prostate cancer	8.09e-07	8.71e-06	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—IL6—prostate cancer	8.04e-07	8.65e-06	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—PTEN—prostate cancer	7.89e-07	8.5e-06	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—AKT1—prostate cancer	7.73e-07	8.32e-06	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—NOS3—prostate cancer	7.64e-07	8.22e-06	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—AKT1—prostate cancer	7.57e-07	8.15e-06	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—AKT1—prostate cancer	7.56e-07	8.13e-06	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—AKT1—prostate cancer	7.53e-07	8.11e-06	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—EP300—prostate cancer	7.53e-07	8.1e-06	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—AKT1—prostate cancer	7.42e-07	7.98e-06	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—PIK3CA—prostate cancer	7.15e-07	7.69e-06	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—PIK3CB—prostate cancer	7.05e-07	7.59e-06	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—PTGS2—prostate cancer	6.99e-07	7.52e-06	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—PIK3CA—prostate cancer	6.98e-07	7.51e-06	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—PIK3CA—prostate cancer	6.57e-07	7.08e-06	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—PTEN—prostate cancer	6.09e-07	6.56e-06	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—AKT1—prostate cancer	5.84e-07	6.28e-06	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—EP300—prostate cancer	5.81e-07	6.25e-06	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—AKT1—prostate cancer	5.7e-07	6.13e-06	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—PIK3CA—prostate cancer	5.57e-07	5.99e-06	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—AKT1—prostate cancer	5.37e-07	5.78e-06	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—AKT1—prostate cancer	4.55e-07	4.9e-06	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—PIK3CA—prostate cancer	4.3e-07	4.63e-06	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—AKT1—prostate cancer	3.51e-07	3.78e-06	CbGpPWpGaD
